U.S. markets closed

Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ)

Shenzhen - Shenzhen Delayed Price. Currency in CNY
Add to watchlist
182.70+3.80 (+2.12%)
As of 10:07AM CST. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close178.90
Bid182.71 x 0
Ask182.80 x 0
Day's Range178.37 - 183.60
52 Week Range92.37 - 231.19
Avg. Volume15,402,379
Market Cap292.32B
Beta (5Y Monthly)0.55
PE Ratio (TTM)78.51
EPS (TTM)2.33
Earnings DateApr 20, 2021
Forward Dividend & Yield0.50 (0.28%)
Ex-Dividend DateAug 12, 2020
1y Target Est58.97
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Bloomberg

      Demand for Online Doctors Creates $39 Billion Titan in Japan

      (Bloomberg) -- Two decades ago, Itaru Tanimura ended a 12-year run at McKinsey & Co. to lead M3 Inc., an online provider of medical information and services backed by entertainment giant Sony Corp.What followed was a flurry of acquisitions that turned the Tokyo-based company into a $39 billion global behemoth. M3 now has about 40 subsidiaries and affiliates, including MDLinx Inc. in the U.S. and Britain’s Doctors.net.uk Ltd.M3 helps pharmaceutical companies, doctors and their patients access information online over its platforms, removing the need for in-person visits -- something that proved important in the time of Covid-19. Its shares have almost doubled this year, surging the most of any company in the Nikkei 225 Stock Average and taking the fortune of Tanimura to $1.2 billion, according to the Bloomberg Billionaires Index.“Online doctor capabilities are in the spotlight with Covid, as people are staying home,” Jefferies Japan Ltd. analyst Hiroko Sato said in an interview. “It’s really a theme stock.”Inquiries SkyrocketThe shares climbed 1.2% by 9:44 a.m. in Tokyo Monday.A rush by smaller pharma companies to digitalize marketing materials after the coronavirus outbreak helped boost sales, with inquiries skyrocketing. M3’s operating profit climbed 26% in the quarter ended in June, beating the highest analyst estimate.The company’s name stands for “the three Ms of Medicine, Media and Metamorphosis,” and its goal is to change medicine by “making full use of the power of the Internet,” according to its website.Its acquisition spree started in 2002, when M3 bought the Japanese unit of U.S. medical portal site WebMD. MDLinx was acquired in 2006 and Doctors.net.uk in 2011. M3, which gets about three-quarters of its revenue from Japan, also has units in China, India and France. One of its U.S. subsidiaries was selected to take part in Moderna Inc.’s Covid-19 vaccine study.Tanimura, 55, is president and holds a 2.9% stake in M3. Sony owns about a third of the company. M3 declined to comment for this story, while Sony didn’t respond to phone calls and an email seeking comment.Tech WealthThe pandemic has produced vast wealth gains among both tech and pharma titans. Amazon.com Inc.’s Jeff Bezos has amassed more than anyone else, with his fortune hitting $200 billion, while Tencent Holdings Ltd.’s Pony Ma and Jiang Rensheng, the chairman of vaccine maker Chongqing Zhifei Biological Products Co., have added more than $11 billion each.While M3 said in its earnings report that Covid-19 disrupted some of its business, it always has Sony to lean on. The entertainment giant unveiled a $100 million relief fund to help tackle the outbreak in April and funneled some of that cash toward M3.“Sony and M3 will be able to bring unprecedented ideas to the medical community,” Tanimura said at the time. “Our first priority will be the rapid development of contributive measures to the fight against Covid-19.”(Adds stock move in fifth paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

    • Reuters

      China's Zhifei starts Phase II trial of COVID-19 vaccine

      A coronavirus vaccine candidate developed by a unit of China's Chongqing Zhifei Biological Products has moved into Phase II human trials, the company said on Friday, less than three weeks after it launched clinical trials. The firm did not provide details of the trial design or results of the Phase I test of the experimental vaccine, being co-developed by Anhui Zhifei Longcom Biopharmaceutical and the Institute of Microbiology of the Chinese Academy of Sciences. Earlier, the company had estimated Phase I trials would be completed on July 21, with the study results expected on Sept 20.

    • Reuters

      Chinese firm gets approval to begin human testing for potential coronavirus vaccine

      China has approved a coronavirus vaccine candidate developed by Chongqing Zhifei Biological Products' unit to begin human testing, the company said in a filing on Tuesday. The potential vaccine, co-developed by Anhui Zhifei Longcom Biopharmaceutical and the Institute of Microbiology of the Chinese Academy of Sciences, has received a certificate from the National Medical Products Administration to launch clinical trials. Chinese researchers and companies are testing six experimental shots in humans, and more than a dozen vaccines are in different stages of clinical trials globally against the virus that has killed over 470,000 people.